Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
docetaxel + vinorelbine + filgrastim
- Development stage
- Unknown
- Lead developer
- Amgen
- Modality
- Recombinant Proteins and Enzymes, Small Molecules
- Administration
- Intravenous, Subcutaneous
01
Overview
docetaxel + vinorelbine + filgrastim is a combination chemotherapy and supportive care regimen evaluated for the treatment of advanced non-small cell lung cancer (NSCLC). The regimen includes docetaxel, a semi-synthetic taxane that stabilizes microtubules to prevent cell division, and vinorelbine, a vinca alkaloid that inhibits microtubule polymerization. To mitigate the hematological toxicity associated with this dose-dense chemotherapy, filgrastim (a recombinant granulocyte colony-stimulating factor) is administered to stimulate neutrophil production and reduce the risk of febrile neutropenia. This specific combination was studied in a Phase II trial sponsored by Amgen, which provided the filgrastim (Neupogen) component.
- Brand names
- TaxotereNavelbineNeupogen
- Other names
- docetaxel and vinorelbine with filgrastim supportdocetaxel-Amgen-non-small cell lung cancer
02
Targets
CSF3R (Granulocyte colony-stimulating factor receptor)
Beyond the preview
Go deeper on docetaxel + vinorelbine + filgrastim.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on docetaxel + vinorelbine + filgrastim.